Skip to main content
Log in

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 1930 patients registered in the Danish Neuro-Oncology Registry (DNOR) from 2009 to 2014. DNOR is a large-scale national population-based database including all adult glioma patients in Denmark. The age-adjusted annual incidence of histologic verified glioma was 7.3 cases pr. 100,000 person-years. High-grade gliomas were present in 85% and low-grade glioma in 15%. The overall male:female ratio was 3:2 and the mean age at onset was 60 years. Data for WHO grade I, II, III and IV glioma showed several important differences regarding age and sex distribution and symptomatology at presentation. The mean age increased with the grade of glioma and males predominated in all grades. Focal deficits were the most frequent presenting symptom, but among patients with glioma, grade II epileptic seizures were the most frequent symptom. Headache was a rare mono-symptomatic onset symptom. At presentation, higher age, focal deficits and cognitive change for <3 months duration, and headache <1 month were significant independent indicators of high-grade gliomas. Younger age and epileptic seizures for more than 3 months were indicative for low-grade gliomas. Survival rates for glioma grade I–IV showed decreasing survival with increasing grade. Glioma grade I–IV showed high diversity regarding several demographic and clinical characteristics emphasizing the importance of individually tailored disease treatments and support.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109(1):93–108

    Article  PubMed  Google Scholar 

  2. Ostrom QT, Bauchet L, Davis FG et al (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology 16(7):896–913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489

    Article  CAS  PubMed  Google Scholar 

  4. NORDCAN (2016) http://www-dep.iarc.fr/NORDCAN/English/frame.asp. Accessed 17 August 2016

  5. The International Classification of Diseases—Oncology, version 3 (ICD-O-3) (2016) http://codes.iarc.fr/. Accessed 17 August 2016

  6. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 14(2):97–109

    Article  Google Scholar 

  7. Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131: 803–820

    Article  PubMed  Google Scholar 

  8. Salminen E, Nuutinen JM, Huhtala S (1996) Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32A(11):1918–1923

    Article  CAS  PubMed  Google Scholar 

  9. Stewart LA (2002) Glioma Metaanalysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018

    Article  CAS  PubMed  Google Scholar 

  10. Ostrom QT, Gittleman H, Stetson L et al (2015) Epidemiology of gliomas. Cancer Treat Res 163:1–14

    Article  PubMed  Google Scholar 

  11. Hansen S, Nielsen J, Laursen RJ et al (2016) The Danish Neuro-Oncology Registry: establishment, completeness and validity. BMC Res Notes 9:425

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hansen S (2016) The Danish Neuro-Oncology Registry. Clin Epidemiol 8:629–632

    Article  PubMed  PubMed Central  Google Scholar 

  13. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  CAS  PubMed  Google Scholar 

  14. Statistics Denmark (2016) http://www.statistikbanken.dk/. Accessed 17 August 2016

  15. Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Posti JP, Bori M, Kauko T et al (2015) Presenting symptoms of glioma in adults. Acta Neurol Scand 131:88–93

    Article  CAS  PubMed  Google Scholar 

  17. Baldi I, Gruber A, Alioum A et al (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000–2007. Neuro-Oncology 13(12):1370–1378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ho VKY, Reijneveld JC, Roelien HE et al (2014) Changing incidence and improved survival of gliomas. Eur J Cancer 50:2309–2318

    Article  PubMed  Google Scholar 

  19. Christensen HC, Kosteljanetz M, Johansen C (2003) Incidence of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery 52:1327–1334

    Article  PubMed  Google Scholar 

  20. Deltour I, Auvinen A, Feychting M et al (2012) Mobile phone use and incidence of glioma in the Nordic countries 1979–2008: consistency check. Epidemiology 23(2):301–307

    Article  PubMed  Google Scholar 

  21. Deltour I, Johansen C, Auvinen A et al (2009) Time trends in brain tumor incidence rates in Denmark, Finland, Norway and Sweden, 1974–2003. J Natl Cancer Inst 101:1721–1724

    Article  PubMed  Google Scholar 

  22. Dahlrot RH, Kristensen BW, Hjelmborg J et al (2013) A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. Int J Clin Exp Pathol 6:31–40

    CAS  PubMed  Google Scholar 

  23. Dahlrot RH, Kristensen BW, Hjelmborg J et al (2013) A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). J Neurooncol 114:309–317

    Article  CAS  PubMed  Google Scholar 

  24. Gittleman HR, Ostrom QT, Rouse CD et al (2015) Trends in Central Nervous System tumor incidence relative to other common cancer in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121:102–112

    Article  PubMed  Google Scholar 

  25. Hamilton W, Kernick D (2007) Clinical features of primary brain tumours: a case-control study using primary care records. Br J Gen Pract 57:695–699

    PubMed  PubMed Central  Google Scholar 

  26. Wöhrer A, Waldhör T, Heinzl M et al (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95:401–411

    Article  PubMed  Google Scholar 

  27. Probst HB, Hussain ZB, Andersen O (2012) Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians—a national Danish project. Health Policy 105:65–70

    Article  PubMed  Google Scholar 

  28. Schmidt-Hansen M, Berendse S, Hamilton W (2015) Symptomatic diagnosis of cancer of the brain and central nervous system in primary care: a systematic review. Fam Pract 32(6):618–623

    Article  PubMed  Google Scholar 

  29. Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349

    Article  CAS  PubMed  Google Scholar 

  30. Rasmussen BK (1995) Epidemiology of headache. Cephalalgia 15:45–68

    Article  CAS  PubMed  Google Scholar 

  31. Laursen EL, Rasmussen BK (2012) A brain cancer pathway in clinical practice. Danish Med J 59(5):A4437

    Google Scholar 

  32. Valentinis L, Tuniz F, Valent et al (2010) Headache attributed to intracranial tumors: a prospective cohort study. Cephalalgia 30(4):389–398

    CAS  PubMed  Google Scholar 

  33. Schankin CJ, Ferrari U, Reinish VM et al (2007) Characteristics of brain tumor-associated headache. Cephalalgia 27:904–911

    Article  CAS  PubMed  Google Scholar 

  34. Kahn K, Finkel A (2014) It IS a tumor—current review of headache and brain tumor. Curr Pain Headache Rep 18:421

    Article  PubMed  Google Scholar 

  35. Goffaux P (2010) Brain tumor headaches: from bedside to bench. Neurosurgery 67:459–466

    Article  PubMed  Google Scholar 

  36. Kirby S, Purdy A (2014) Headaches and brain tumors. Neurol Clin 32:423–432

    Article  PubMed  Google Scholar 

  37. De Luca GC, Bartleson JD (2010) When and how to investigate the patient with headache. Semin Neurol 30(2):131–144

    Article  PubMed  Google Scholar 

  38. Schwartzbaum J, Jonsson F, Ahlbom A et al (2005) Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Biomarkers Prev 14:643–650

    Article  PubMed  Google Scholar 

  39. Tucha O, Smely C, Preier M et al (2000) Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 47:324–334

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all the contributing departments for reporting data to DNOR, and we thank Susanne Møllerstrøm for language editing.

Funding

The Danish Cancer Society (R94-A5827).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Steinbjørn Hansen.

Ethics declarations

Conflict of interest

None of the authors have any competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rasmussen, B.K., Hansen, S., Laursen, R.J. et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry. J Neurooncol 135, 571–579 (2017). https://doi.org/10.1007/s11060-017-2607-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2607-5

Keywords

Navigation